Disc Medicine Analyst Ratings
Disc Medicine Price Target Maintained With a $85.00/Share by Cantor Fitzgerald
HC Wainwright & Co. Reiterates Buy on Disc Medicine, Maintains $70 Price Target
H.C. Wainwright Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $70
Buy Rating Affirmed for Disc Medicine on Promising Drug Pipeline and Strategic Developments
Disc Medicine Analyst Ratings
Wells Fargo Initiates Disc Medicine at Overweight With $75 Price Target
Wells Fargo Initiates Disc Medicine(IRON.US) With Buy Rating, Announces Target Price $75
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Natera (NTRA) and Disc Medicine (IRON)
Disc Medicine Analyst Ratings
Wedbush Reiterates Outperform on Disc Medicine, Maintains $57 Price Target
Disc Medicine (IRON) Gets a Hold From Morgan Stanley
Disc Medicine (IRON) Receives a New Rating From Wedbush
Buy Rating Affirmed on Disc Medicine's Strong Clinical Pipeline and Financial Health
Buy Rating Affirmed for Disc Medicine on Strong Financials and Positive Clinical Trials
Disc Medicine Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Disc Medicine, Maintains $70 Price Target
Buy Rating Affirmed: Strong Phase 2 Results and Strategic FDA Engagement Bolster Confidence in Disc Medicine's Pipeline
BMO Capital Reiterates Outperform on Disc Medicine, Raises Price Target to $70
Wedbush Raises Disc Medicine Price Target to $57 From $43, Maintains Outperform Rating